Accra has turned down a health agreement with Washington, citing access to medical records, pathogen information and alleged restrictions on drug oversight. The decision has reignited the debate over Africa’s health sovereignty.
Accra — Ghana has raised a question that stretches far beyond its own health system: what is a country’s sovereignty worth when foreign financial aid comes with sensitive conditions attached?
The answer from Accra is now clear: not $109 million.
The Ghanaian government refused a new health agreement proposed by the United States, which would have provided roughly $109 million in American funding over five years. The overall programme was valued at about $300 million, taking into account expected complementary contributions from Ghana.
President John Dramani Mahama confirmed and explained the rejection during a speech at the Council on Foreign Relations in New York on 25 September.
And his words struck a chord.
« Who takes another country’s medical records? »
According to the Ghanaian president, the draft agreement included provisions for transmitting Ghana’s pathogen profiles and medical data to the United States. He also said the text required Ghana to provide counterpart funding and contained clauses on the control of medical products entering the country.
For Mahama, these conditions were simply “humiliating”.
What Washington was actually asking for
The matter deserves a closer look beyond the headline-grabbing phrase.
Ghana did not reject a $100 million package simply because it came from the United States. The problem lies in the conditions attached to the funding.
The Associated Press reported in May that the draft agreement, worth about $300 million overall, would have brought Ghana approximately $109 million over five years. Arnold Kavaarpuo, executive director of Ghana’s Data Protection Commission and a participant in the negotiations, said some provisions would have allowed access to sensitive health data in circumstances that could potentially identify individuals. According to him, the scope of that access went far beyond what is normally necessary.
The BMJ also reported that the Ghanaian draft provided for access to health data and pathogens for 16 American companies. The journal noted, however, that several clauses of the new US health agreements remain difficult to examine publicly, because not all negotiated texts have been made public.
This is where a nuance is needed: it would be excessive to claim that the United States was demanding unrestricted access to “all Ghanaians’ medical data”. What is documented, however, are Ghanaian concerns about the extent of access to health data and pathogen information.
Why this data matters so much
Behind medical records lies a real question of power.
Health data reveals which diseases are circulating, where they are spreading, which populations are most exposed and how epidemics are evolving.
Pathogen data can also have considerable scientific value. It can contribute to research on vaccines, treatments and surveillance of new outbreaks.
This is precisely what is fuelling concerns among several African governments.
In February 2026, Jean Kaseya, director general of the Africa Centres for Disease Control and Prevention (Africa CDC), had already expressed serious concerns about provisions on data and pathogen sharing in the new US health agreements. Reuters reported at the time that some agreements required rapid sharing of sensitive data without guaranteeing African countries access to treatments or vaccines that might result from that information.
Ghana is therefore not an isolated case.
Accra no longer wants to depend entirely on foreign aid
The rejection also comes in a particular context.
Since the suspension of a large part of US aid programmes, Ghana has been seeking to reduce its dependence on external funding. In February 2025, the Ghanaian presidency already estimated the shortfall caused by the suspension of USAID funding at $156 million, of which $78.2 million directly concerned essential health programmes.
The Mahama government is now pushing the idea of “health sovereignty”.
This direction was reinforced in September with the launch of the report A Sovereign Future for Health, presented as part of the Accra Reset initiative. The document proposes, among other things, reducing the dependence of Global South countries on external funding and strengthening their own health systems.
Accra’s message is therefore relatively clear: Ghana wants to continue working with its foreign partners, but on the basis of agreements it considers more balanced.
Another sticking point: medicines
The other element revealed by Mahama is particularly sensitive.
According to the president, the draft agreement provided that certain medicines and medical products supplied under the programme would not be subject to controls by Ghana’s Food and Drugs Authority (FDA).
This claim has not been publicly confirmed in detail by the US government, which, when asked by the Associated Press, said it does not comment on the details of bilateral negotiations.
But if this provision does match the text presented to the Ghanaian government, it explains part of Accra’s firmness: for the authorities, health funding should not lead to reducing the national regulator’s ability to control medical products used on its territory.
And the American response?
Washington has not publicly detailed the contested clauses.
A spokesperson for the US State Department said the United States does not disclose the details of bilateral negotiations, while stating that Washington is still looking for ways to strengthen its partnership with Ghana.
This lack of full publication of the text therefore prevents certain essential questions from being settled.
Exactly what data would have been accessible?
To which American companies or institutions?
Under what circumstances could individuals have been identified?
How long would the data have been retained?
What legal guarantees would have protected Ghanaian patients?
On these points, public information remains incomplete.
Ghana opens a debate that goes beyond Ghana
The real issue in this case may lie there.
For decades, many African health systems have depended on funding, medicines, equipment and programmes from abroad. These partnerships have helped save lives and fight major diseases.
But the digital transformation of health is now changing the nature of cooperation.
Aid is no longer just about money, medicines or equipment. It can also give access to a strategic resource: data.
And Ghana has just reminded everyone that it intends to keep control of that resource.
John Mahama says his government rejected the draft after it was reviewed by the Ministry of Health and passed before the Cabinet. He also says the decision had the support of the entire government and that the rejection was decided very quickly.
Ghana will now have to demonstrate that it can fill the abandoned funding gap without compromising its health programmes.
But for Accra, the choice seems deliberate:
better to look for other partners than to conclude an agreement the government considers incompatible with health sovereignty and the protection of Ghanaians’ data.
The question Ghana is now putting to its foreign partners is simple:
When Africa receives aid to treat its populations, must it also surrender control over information about those populations?
The debate is probably only just beginning.
